Skip to content

Study · Case report or series · n = 3 · 2011

1 result

Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism.

Linglart A, Rothenbuhler A, Gueorgieva I, Lucchini P, Silve C, Bougnères P

The Journal of clinical endocrinology and metabolism24 Aug 2011Cited by 47 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In three children with hypoparathyroidism, continuous subcutaneous rhPTH(1-34) treatment was reported as successful, without quantitative outcomes.

    In plain wordsIn three children with hypoparathyroidism, continuous teriparatide treatment was reported as successful, without detailed results.

    Outcome
    Not applicableHypoparathyroidism treatment success
    Study

    n = 3

    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · continuous subcutaneous administrationAs given in this study (human).

    Source sentences

    Summary
    We successfully treated three patients with hypoparathyroidism with continuous subcutaneous administration of rhPTH(1-34) (recombinant human PTH(1-34)), two of which were refractory to conventional therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.